FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078289731> ?p ?o ?g. }

• W2078289731 endingPage "240" @default.
• W2078289731 startingPage "231" @default.
• W2078289731 abstract "Poor solubility of etoposide and associated poor bioavailability of the drug was circumvented by developing solid lipid nanocarrier system. The objective of the research work was to prepare etoposide loaded solid lipid nanoparticles (SLN) for improved efficacy and therapy of metastasized cancers. Entrapment of drug into nanoparticulate system modifies the pharmacokinetic and biodistribution profile of the drug with improved therapeutic efficacy. Solid lipid nanoparticles of various triglycerides were prepared using hot homogenization technique. Further, the process and formulation parameters viz. homogenization cycle and pressure, type of lipid were optimized. Developed nanoparticles were characterised for particle size, in vitro dissolution studies, DSC thermogram, surface morphology and cytotoxicity assay. Pharmacokinetic and biodistribution study were performed to assess the distribution of the drug in vivo. Modulation of the therapeutic activity of the drug was studied by performing antimetastatic activity on a B16F10 melanoma mouse model. The obtained results exhibited suitability of trimysristin for fabrication of nanoparticles. Characterisation of nanoparticles depicted formation of homogenous, spherical particles entrapping approximately 50% of the drug. The results for the performed MTT assay suggested that the developed nanoparticles exhibited cytotoxicity in a time- and concentration-dependent fashion. These findings concord with the results of the in vitro dissolution profile. Pharmacokinetic parameters demonstrated increase in area under curve (AUC), t1/2 and mean residence time (MRT) for drug in plasma. Further there is enhancement in the ratio of the drug that reaches to the highly perfused organs (upon encapsulation into solid lipid nanoparticles). Generally, cancer cells metastasized through the blood or lymphatic system. Accumulation of the drug in the highly perfused organ suggests suitability of the developed nanoparticles for targeting metastasized tumors. This was proved by the findings of the in vivo B16F10 mouse melanoma model. Improvement in the tumoricidal activity and survival rate of the animals substantiates the application of nanoparticles for improved therapeutic activity of etoposide." @default.
• W2078289731 created "2016-06-24" @default.
• W2078289731 creator A5024606837 @default.
• W2078289731 creator A5025065295 @default.
• W2078289731 creator A5046675352 @default.
• W2078289731 creator A5078158266 @default.
• W2078289731 date "2014-03-01" @default.
• W2078289731 modified "2023-10-17" @default.
• W2078289731 title "Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung" @default.
• W2078289731 cites W1965326858 @default.
• W2078289731 cites W1969272850 @default.
• W2078289731 cites W1979151430 @default.
• W2078289731 cites W1986919257 @default.
• W2078289731 cites W2018898714 @default.
• W2078289731 cites W2054189154 @default.
• W2078289731 cites W2100151202 @default.
• W2078289731 cites W2136896155 @default.
• W2078289731 cites W2144417922 @default.
• W2078289731 cites W2273495465 @default.
• W2078289731 doi "https://doi.org/10.1016/j.biopha.2014.01.004" @default.
• W2078289731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24560352" @default.
• W2078289731 hasPublicationYear "2014" @default.
• W2078289731 type Work @default.
• W2078289731 sameAs 2078289731 @default.
• W2078289731 citedByCount "29" @default.
• W2078289731 countsByYear W20782897312015 @default.
• W2078289731 countsByYear W20782897312016 @default.
• W2078289731 countsByYear W20782897312017 @default.
• W2078289731 countsByYear W20782897312018 @default.
• W2078289731 countsByYear W20782897312019 @default.
• W2078289731 countsByYear W20782897312020 @default.
• W2078289731 countsByYear W20782897312021 @default.
• W2078289731 countsByYear W20782897312022 @default.
• W2078289731 countsByYear W20782897312023 @default.
• W2078289731 crossrefType "journal-article" @default.
• W2078289731 hasAuthorship W2078289731A5024606837 @default.
• W2078289731 hasAuthorship W2078289731A5025065295 @default.
• W2078289731 hasAuthorship W2078289731A5046675352 @default.
• W2078289731 hasAuthorship W2078289731A5078158266 @default.
• W2078289731 hasConcept C109316439 @default.
• W2078289731 hasConcept C112705442 @default.
• W2078289731 hasConcept C126322002 @default.
• W2078289731 hasConcept C13245373 @default.
• W2078289731 hasConcept C150903083 @default.
• W2078289731 hasConcept C155672457 @default.
• W2078289731 hasConcept C171250308 @default.
• W2078289731 hasConcept C181389837 @default.
• W2078289731 hasConcept C18150654 @default.
• W2078289731 hasConcept C185592680 @default.
• W2078289731 hasConcept C192562407 @default.
• W2078289731 hasConcept C199529486 @default.
• W2078289731 hasConcept C202751555 @default.
• W2078289731 hasConcept C204399865 @default.
• W2078289731 hasConcept C207001950 @default.
• W2078289731 hasConcept C2776694085 @default.
• W2078289731 hasConcept C2777807558 @default.
• W2078289731 hasConcept C2778119113 @default.
• W2078289731 hasConcept C2780035454 @default.
• W2078289731 hasConcept C2780783641 @default.
• W2078289731 hasConcept C55493867 @default.
• W2078289731 hasConcept C71924100 @default.
• W2078289731 hasConcept C86803240 @default.
• W2078289731 hasConcept C98274493 @default.
• W2078289731 hasConceptScore W2078289731C109316439 @default.
• W2078289731 hasConceptScore W2078289731C112705442 @default.
• W2078289731 hasConceptScore W2078289731C126322002 @default.
• W2078289731 hasConceptScore W2078289731C13245373 @default.
• W2078289731 hasConceptScore W2078289731C150903083 @default.
• W2078289731 hasConceptScore W2078289731C155672457 @default.
• W2078289731 hasConceptScore W2078289731C171250308 @default.
• W2078289731 hasConceptScore W2078289731C181389837 @default.
• W2078289731 hasConceptScore W2078289731C18150654 @default.
• W2078289731 hasConceptScore W2078289731C185592680 @default.
• W2078289731 hasConceptScore W2078289731C192562407 @default.
• W2078289731 hasConceptScore W2078289731C199529486 @default.
• W2078289731 hasConceptScore W2078289731C202751555 @default.
• W2078289731 hasConceptScore W2078289731C204399865 @default.
• W2078289731 hasConceptScore W2078289731C207001950 @default.
• W2078289731 hasConceptScore W2078289731C2776694085 @default.
• W2078289731 hasConceptScore W2078289731C2777807558 @default.
• W2078289731 hasConceptScore W2078289731C2778119113 @default.
• W2078289731 hasConceptScore W2078289731C2780035454 @default.
• W2078289731 hasConceptScore W2078289731C2780783641 @default.
• W2078289731 hasConceptScore W2078289731C55493867 @default.
• W2078289731 hasConceptScore W2078289731C71924100 @default.
• W2078289731 hasConceptScore W2078289731C86803240 @default.
• W2078289731 hasConceptScore W2078289731C98274493 @default.
• W2078289731 hasIssue "2" @default.
• W2078289731 hasLocation W20782897311 @default.
• W2078289731 hasLocation W20782897312 @default.
• W2078289731 hasOpenAccess W2078289731 @default.
• W2078289731 hasPrimaryLocation W20782897311 @default.
• W2078289731 hasRelatedWork W197819064 @default.
• W2078289731 hasRelatedWork W2002675502 @default.
• W2078289731 hasRelatedWork W2032804376 @default.
• W2078289731 hasRelatedWork W2167016467 @default.
• W2078289731 hasRelatedWork W2341080712 @default.
• W2078289731 hasRelatedWork W2559967503 @default.

• next